AstraZeneca PLC: Key FDA Approvals and Market Impact (18 May 2026)

AstraZeneca PLC (London: AZN) received several U.S. Food and Drug Administration (FDA) approvals on 18 May 2026 that broaden its therapeutic portfolio and potentially generate new revenue streams.

FDA Approval of BAXFENDY™ (baxdrostat)

On 18 May, the FDA granted approval for BAXFENDY™, a first‑in‑class aldosterone synthase inhibitor, for the treatment of adults with hypertension. The approval was announced by the company and reported by multiple outlets, including grafa.com, finanznachrichten.de, avanza.se, and tipranks.com. The drug is intended for patients who remain hypertensive despite standard therapy. The approval positions BAXFENDY™ as a unique addition to the antihypertensive market and may create a new revenue stream in a therapeutic area where AstraZeneca has had limited exposure.

FDA Approval of Enhertu (trastuzumab deruxtecan)

In the same period, AstraZeneca, in partnership with Daiichi Sankyo, secured FDA approval for Enhertu for two new indications in HER2‑positive early breast cancer in the neoadjuvant and adjuvant settings. The decision, reported by finanznachrichten.de and avanza.se, expands the use of Enhertu beyond its previous approval for metastatic disease. The expansion may strengthen AstraZeneca’s oncology pipeline, particularly in the HER2‑positive breast cancer segment.

Digital Pathology Initiative with Roche

A separate announcement, sourced from avanza.se, detailed a collaboration with Roche to advance digital pathology for breast and lung cancer in Asia. While not a regulatory approval, the partnership signals AstraZeneca’s commitment to integrating digital diagnostics into its oncology portfolio.

Market Reaction

Despite the regulatory milestones, AstraZeneca’s shares fell 1.8 % early on 18 May, as noted by tipranks.com. The decline was attributed to investor concerns that the newly approved drugs may not reach blockbuster status in the short term. The stock closed on 17 May at £13.710 (GBX 13,710), within a 52‑week range of £10,103 to £15,732. The company’s price‑to‑earnings ratio stands at 27.65.

Company Profile

AstraZeneca PLC is a holding company headquartered in Cambridge, United Kingdom, operating within the health‑care sector. It conducts research, manufacturing, and sales across eight therapeutic areas: gastrointestinal, oncology, cardiovascular, respiratory, central nervous system, pain control, anaesthesia, and infection. The company is listed on the London Stock Exchange, with a market capitalization of £282 872 167 500 (GBX). Its IPO dates back to 12 May 1993.

Source citations

  • grafa.com – FDA approval of BAXFENDY™.
  • finanznachrichten.de – FDA approvals of BAXFENDY and Enhertu.
  • avanza.se – Digital pathology collaboration and FDA approvals.
  • tipranks.com – Market reaction.
  • Fundamentals – Company overview and financial data.